ArticleCancer immunology research2021

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.

Hikmat H Assi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.